Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona diagnoza zespołu karcinoidu wymagająca leczenia
- •Średnio więcej niż 1 atak zaczerwienienia na dzień przez 14 dni
- •Potwierdzony nowotwór neuroendokrynny rozprzestrzeniający się na inne narządy lub tkanki
- •Brak znacznego pogorszenia się choroby w ciągu ostatnich 6 miesięcy
- •Gotowość do prowadzenia dziennika objawów przez 2 tygodnie ze zgodą co najmniej 70%
✗ Disqualifies
- •Biegunka spowodowana inną chorobą niż zespół karcinoidu
- •Ciężka biegunka ze znacznym odwodnieniem organizmu
- •Konieczność zastosowania innych leków drugiej linii do kontroli objawów
- •Leczenie chemią lub radioterapia mniej niż 4 tygodnie przed badaniem
- •Duża operacja chirurgiczna w ciągu 8 tygodni przed badaniem
- •Historia innego nowotworu w ciągu ostatnich 3 lat (z wyjątkami na skórę)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (67)
Banner MD Anderson Cancer Center
Gilbert, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, United States
Yale University - New Haven Hospital - Yale Cancer Center
New Haven, United States
University of Miami
Miami, United States
Moffitt Cancer Center
Tampa, United States
Winshop Cancer Institute - Emory University
Atlanta, United States
University of Iowa Health Care
Iowa City, United States
University of Kentucky Medical Center
Lexington, United States
Louisiana State University Health Sciences
Metairie, United States
Henry Ford Cancer - Detroit
Detroit, United States
Mayo Clinic
Rochester, United States
Icahn School of Medicine at Mount Sinai
New York, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
Hospital of the University of Pennsylvania
Philadelphia, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
University of Virginia Comprehensive Cancer Center
Charlottesville, United States
Medical College of Wisconcin
Milwaukee, United States
Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo
Buenos Aires, Argentina
Sanatorio Guemes
Buenos Aires, Argentina
Centro de Endocrinologia y Diabetes Dr. A. Gutman ICM - Investigaciones
Buenos Aires, Argentina
Instituto Médico Especializado Alexander Fleming
Buenos Aires, Argentina
Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo
CABA, Argentina
Instituto Médico de la Fundación Estudios Clínicos
Santa Fe, Argentina
AC Camargo Cancer Center
São Paulo, Brazil
Fundacao PIO XII - Hospital de Amor Barretos
Barretos, Brazil
Sociedade Literaria e Caritativa Santos Agostinho - Hospital Sao José
Criciúma, Brazil
Nucleo de Pesquisa e Desenvolvimento de Medicamentos (MPDM)
Fortaleza, Brazil
Associacao Hospitalar Moinhos de Vento
Porto Alegre, Brazil
Instituto Nacional de Cancer (INCA)
Rio de Janeiro, Brazil
Clinical Universidad Catolica del Maule, Ltda
Maule, Chile
Centro de Oncologia de Precision
Santiago, Chile
CECIM-Centro de Estudios Cliicos e Investigaciones Medicas
Santiago, Chile
Hospital Universitario San Ignacio
Bogotá, Colombia
Instituto Nacional de Cancerologia
Bogotá, Colombia
CHRU Tours - Hopital Trousseau
Chambray-lès-Tours, France
Hopital Beaujun - APHP
Clichy, France
APHM- Hopital de la Timone
Marseille, France
Centre Hospitalier Universitaire Nantes
Nantes, France
Centre Antoine Lacassagne
Nice, France
CHU Bordeaux - Hopital Haut-Leveque
Pessac, France
Asklepios Kilnic St. Georg
Hamburg, Germany
Universitätsklinikum Marburg (UKGM)
Marburg, Germany
Instituto Europeo di Oncologia
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza Di Torino
Turin, Italy
Health Pharma Professional Research S.A de C.V.
Mexico City, Mexico
Centro de Oncolégica VIVA
Mexico City, Mexico
Uniwersyteckie Centrum Kliniczne im. Prof K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach
Katowice, Poland
Centrum Diagnostyczno-Lecznicze ,,GAMMED"
Warsaw, Poland
Wokskowy Instytut Medyczny - Panstwowy Instytut Badawczy, Centrum Wsparcia Badań Klinicznych
Warsaw, Poland
Institute of Oncology Bucharest
Bucharest, Romania
Institute of Oncology "Prof. Dr. Ion Chiricuta" Cluj Napoca
Cluj-Napoca, Romania
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Fundacion Jimenez Diaz University Hospital
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitario y Politecnico La Fe
Valencia, Spain
King's College Hospital
London, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Queen Elizabeth Hospital Brimingham
Birmingham, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
The Beatson WOS Cancer Centre
Glasgow, United Kingdom
Royal Free Hospital
London, United Kingdom
NIHR Clinical Research Facility, Royal Hallamshire Hospital
Sheffield, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Trial contact
Crinetics Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.